Recommended Readings: Howard C Hang, PhD.

Chemical Reporters for Exploring Posttranslational

Modifications in Innate Immunity

Howard C Hang, Ph.D.

Laboratory of Chemical Biology and Microbial Pathogenesis

The Rockefeller University

4:00 p.m. Monday, June 4, 2012    Refreshments  3:45  Abby Lounge

Caspary Auditorium

Recommended Readings

Yount JS, Charron G, Hang HC.   2012.  Bioorthogonal proteomics of 15-hexadecynyloxyacetic acid chemical reporter reveals preferential targeting of fatty acid modified proteins and biosynthetis enzymes.    Bioorganic & Medicinal Chemistry.  20(2, S1):650-654.  DOI: 0.1016/j.bmc.2011.03.062

Lei YL, Xie K. et al.  2012.  Chemistry-based functional proteomics to identify novel deubiquitylating enzymes involved in viral infection.   Combinatorial Chemistry & High Throughput Screening.  15(4):316-327.   Please request from Markus Library.

Grammel M, Dossa PD, Taylor-Salmon E, et al.  2012.  II-selective labeling of bacterial proteomes with an  orthogonal phenylalanine amino acid reporter.   Chemical Communications.  48(10):1473-1474.  DOI: 10.1039/c1cc14939c

Aguera-Gonzales S, Gross CC, Fernandez-Messina L, et al.  2011.  Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding   European Journal of Immunology.  41(12):3667-3676.   DOI: 10.1002/eji.20114165

Hao ZY, Hong SL, Chen X, et al.  2011.  Introducing bioorthogonal functionalities into proteins in living cellsAccounts of Chemical Research   44(9, S1):742-751.   DOI: 10.1021/ar200067r

Hang HC, Linder ME.  2011.  Exploring protein lipidation with chemical biology.  Chemical Reviews.  111(10):6341-6358.   DOI:  10.1021/cr2001977

Yang YY, Hang HC.  2011.  Chemical approaches for the detection and synthesis of acetylated proteins.  Chembiochem.   12(2):314-322.   DOI: 10.1002/cbc.201000558

 

 

 

Absence of Evidence: How Big Pharma Spins the Data

Absence of evidence

Nov 27th 2008 | NEW YORK
From The Economist print edition

Do drug firms suppress unfavourable information about new products?

 

RICHARD FEYNMAN, a Nobel-prize-winning physicist, declared in a speech in 1974 that science requires “a kind of utter honesty”. He insisted that researchers must publicise all the outcomes of their work, and “not just the information that leads to judgment in one particular direction or another”. To judge by the mounting evidence of publication bias involving studies on new drugs, his words have not yet reached the pharmaceuticals industry.

A study published this week in PLoS Medicine, an online journal, confirms what many have suspected and what previous studies have hinted at: drug companies try to spin the results of clinical trials. If this were done merely in marketing materials, it might be tolerable. What Lisa Bero of the University of California, San Francisco, and her colleagues found, however, was troubling evidence of suppression and manipulation of data in studies published in (or often withheld from) peer-reviewed medical journals.